155 related articles for article (PubMed ID: 12589602)
1. [Clinical evaluation of multiple sclerosis: quantification by use of scales].
Izquierdo G; Ruiz-Peña JL
Rev Neurol; 2003 Jan 16-31; 36(2):145-52. PubMed ID: 12589602
[TBL] [Abstract][Full Text] [Related]
2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
Ozakbas S; Cagiran I; Ormeci B; Idiman E
J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
[TBL] [Abstract][Full Text] [Related]
3. [A study of various scales of fatigue and impact on the quality of life among patients with multiple sclerosis].
Casanova B; Coret F; Landete L
Rev Neurol; 2000 Jun 16-30; 30(12):1235-41. PubMed ID: 10935257
[TBL] [Abstract][Full Text] [Related]
4. Cognitive fatigue in multiple sclerosis: findings from a two-wave screening project.
Barak Y; Achiron A
J Neurol Sci; 2006 Jun; 245(1-2):73-6. PubMed ID: 16626750
[TBL] [Abstract][Full Text] [Related]
5. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
[TBL] [Abstract][Full Text] [Related]
6. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
[TBL] [Abstract][Full Text] [Related]
7. Validity of performance scales for disability assessment in multiple sclerosis.
Marrie RA; Goldman M
Mult Scler; 2007 Nov; 13(9):1176-82. PubMed ID: 17623733
[TBL] [Abstract][Full Text] [Related]
8. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients.
Yozbatiran N; Baskurt F; Baskurt Z; Ozakbas S; Idiman E
J Neurol Sci; 2006 Jul; 246(1-2):117-22. PubMed ID: 16678208
[TBL] [Abstract][Full Text] [Related]
9. [Sleepiness and fatigue in multiple sclerosis - comparison of different measuring instruments].
Kotterba S; Eren E; Fangerau T; Malin JP; Sindern E
Fortschr Neurol Psychiatr; 2003 Nov; 71(11):590-4. PubMed ID: 14608510
[TBL] [Abstract][Full Text] [Related]
10. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy.
Ozakbas S; Akdede BB; Kösehasanogullari G; Aksan O; Idiman E
J Neurol Sci; 2007 May; 256(1-2):30-4. PubMed ID: 17379247
[TBL] [Abstract][Full Text] [Related]
11. [Neuropsychological evaluation in multiple sclerosis].
Arnett P; Forn C
Rev Neurol; 2007 Feb 1-15; 44(3):166-72. PubMed ID: 17285522
[TBL] [Abstract][Full Text] [Related]
12. [Searching for more specific dimensions for the measurement of quality of life in multiple sclerosis].
Rivera-Navarro J; Benito-León J; Morales-González JM
Rev Neurol; 2001 Apr 16-30; 32(8):705-13. PubMed ID: 11391503
[TBL] [Abstract][Full Text] [Related]
13. [Validation of the Japanese-translated version Multiple Sclerosis Quality of Life-54 instrument].
Yamamoto T; Ogata K; Katagishi M; Shimizu H; Ogawa M; Yamamura T; Kawai M
Rinsho Shinkeigaku; 2004 Jul; 44(7):417-21. PubMed ID: 15384701
[TBL] [Abstract][Full Text] [Related]
14. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
16. [Impairment, disability and handicap scales in multiple sclerosis].
Arbizu-Urdiain T; Martínez-Yélamos A; Casado Ruiz V
Rev Neurol; 2002 Dec 1-15; 35(11):1081-93. PubMed ID: 12497316
[TBL] [Abstract][Full Text] [Related]
17. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
[TBL] [Abstract][Full Text] [Related]
18. [Energy-saving strategies in the treatment of fatigue in patients with multiple sclerosis. A pilot study].
García-Burguillo MP; Aguila-Maturana AM
Rev Neurol; 2009 Aug 16-31; 49(4):181-5. PubMed ID: 19621319
[TBL] [Abstract][Full Text] [Related]
19. Fatigue in multiple sclerosis is related to disability, depression and quality of life.
Pittion-Vouyovitch S; Debouverie M; Guillemin F; Vandenberghe N; Anxionnat R; Vespignani H
J Neurol Sci; 2006 Apr; 243(1-2):39-45. PubMed ID: 16434057
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations.
Rogers JM; Panegyres PK
J Clin Neurosci; 2007 Oct; 14(10):919-27. PubMed ID: 17659875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
